

COPY OF PAPERS ORIGINALLY FILED



PATENT Docket No. 11245/46604

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

WAKSAL, Harlan W.

RECEIVED

Application No.: 09/840,146

FEB 2 6 2002 Examiner: Hunt, Jennifer

Filing Date:

April 24, 2001

TECH CENTER 1600/2900

1642

For:

TREATMENT OF REFRACTORY

HUMAN TUMORS

WITH EPIDERMAL \mathfrak{l} contributed with the GROWTH FACTOR United States Postal Service as first class mail in an envelope orderessed to: Assistant Commissioner for Patents, Washington

RECEPTOR **ANTAGONISTS**

D.C. 20231, on

Art Unit:

Commissioner of Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It has come to applicants' attention that a patent application related to the treatment of colorectal cancer with an agent capable of blocking the binding of EGFR to its natural ligand(s), for example, an EGFR antibody, and/or inhibiting EGFRmediated signaling has apparently been filed in the U.S. Patent and Trademark Office on behalf of Dr. Mark Rubin. It is our understanding that Dr. Rubin's application was filed in March of 2001; however, we do not know the exact filing date or the application number assigned thereto. Although applicants do not believe that any such application would be considered prior art to the present invention under 35

U.S.C. § 102, a copy of Form PTO-1449 is attached hereto listing Dr. Rubin's application.

Applicants believe that the present application is in condition for allowance, and respectfully request that the Office pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite prosecution of the present application, or if there is any difficulty in locating Dr. Rubin's application, please contact the undersigned attorney.

The Office is authorized to charge any fees that may be necessary for consideration of this paper to Kenyon & Kenyon Deposit Account No. 11-0600.

Respectfully submitted,

Deborah A. Somerville, Reg. No. 31,995

KENYON & KENYON

One Broadway

New York, NY 10004

(212) 908-6277 (telephone)

(212) 425-5288 (facsimile)

Dated: January 30, 2002